Prescription patterns in patients with schizophrenia in Japan: First‐quality indicator data from the survey of "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)" project
Abstract Background Guideline for Pharmacological Therapy for Schizophrenia was published by the Japanese Society of Neuropsychopharmacology in 2015. "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)" project aimed to standardize medical practic...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Book |
Published: |
Wiley,
2020-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_3336c28c1c5847f78bd5f90f46bc9a25 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Kayo Ichihashi |e author |
700 | 1 | 0 | |a Hikaru Hori |e author |
700 | 1 | 0 | |a Naomi Hasegawa |e author |
700 | 1 | 0 | |a Yuka Yasuda |e author |
700 | 1 | 0 | |a Tomoya Yamamoto |e author |
700 | 1 | 0 | |a Takashi Tsuboi |e author |
700 | 1 | 0 | |a Kunihiro Iwamoto |e author |
700 | 1 | 0 | |a Taishiro Kishimoto |e author |
700 | 1 | 0 | |a Tadasu Horai |e author |
700 | 1 | 0 | |a Hiroki Yamada |e author |
700 | 1 | 0 | |a Nobuhiro Sugiyama |e author |
700 | 1 | 0 | |a Toshinori Nakamura |e author |
700 | 1 | 0 | |a Naohisa Tsujino |e author |
700 | 1 | 0 | |a Kiyotaka Nemoto |e author |
700 | 1 | 0 | |a Satoru Oishi |e author |
700 | 1 | 0 | |a Masahide Usami |e author |
700 | 1 | 0 | |a Eiichi Katsumoto |e author |
700 | 1 | 0 | |a Hidenaga Yamamori |e author |
700 | 1 | 0 | |a Hiroaki Tomita |e author |
700 | 1 | 0 | |a Taro Suwa |e author |
700 | 1 | 0 | |a Ryuji Furihata |e author |
700 | 1 | 0 | |a Takahiko Inagaki |e author |
700 | 1 | 0 | |a Junichi Fujita |e author |
700 | 1 | 0 | |a Toshiaki Onitsuka |e author |
700 | 1 | 0 | |a Kenichiro Miura |e author |
700 | 1 | 0 | |a Junya Matsumoto |e author |
700 | 1 | 0 | |a Kazutaka Ohi |e author |
700 | 1 | 0 | |a Yuki Matsui |e author |
700 | 1 | 0 | |a Yoshikazu Takaesu |e author |
700 | 1 | 0 | |a Naoki Hashimoto |e author |
700 | 1 | 0 | |a Junichi Iga |e author |
700 | 1 | 0 | |a Kazuyoshi Ogasawara |e author |
700 | 1 | 0 | |a Hisashi Yamada |e author |
700 | 1 | 0 | |a Koichiro Watanabe |e author |
700 | 1 | 0 | |a Ken Inada |e author |
700 | 1 | 0 | |a Ryota Hashimoto |e author |
245 | 0 | 0 | |a Prescription patterns in patients with schizophrenia in Japan: First‐quality indicator data from the survey of "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)" project |
260 | |b Wiley, |c 2020-09-01T00:00:00Z. | ||
500 | |a 2574-173X | ||
500 | |a 10.1002/npr2.12122 | ||
520 | |a Abstract Background Guideline for Pharmacological Therapy for Schizophrenia was published by the Japanese Society of Neuropsychopharmacology in 2015. "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)" project aimed to standardize medical practice using quality indicators (QIs) as indices to evaluate the quality of medical practice. In this study, we have reported the quality indicator values of prescription before the beginning of the guideline lectures in the EGUIDE project to ascertain the baseline status of treating patients with schizophrenia. Methods A cross‐sectional, retrospective case record survey was conducted, involving 1164 patients with schizophrenia at the time of discharge. We checked all types and dosage of psychotropic drugs. Results Forty‐three percent of patients had antipsychotic polypharmacy, and substantial concomitant medication was observed (antidepressants; 8%, mood stabilizers: 37%, anxiolytics or hypnotics: 68%). Conclusions In the results obtained in this study, we plant to report changes in the effectiveness of education in the EGUIDE project near the future. | ||
546 | |a EN | ||
690 | |a antipsychotics | ||
690 | |a EGUIDE project | ||
690 | |a guideline | ||
690 | |a quality indicator | ||
690 | |a schizophrenia | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
690 | |a Neurosciences. Biological psychiatry. Neuropsychiatry | ||
690 | |a RC321-571 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Neuropsychopharmacology Reports, Vol 40, Iss 3, Pp 281-286 (2020) | |
787 | 0 | |n https://doi.org/10.1002/npr2.12122 | |
787 | 0 | |n https://doaj.org/toc/2574-173X | |
856 | 4 | 1 | |u https://doaj.org/article/3336c28c1c5847f78bd5f90f46bc9a25 |z Connect to this object online. |